Physician

Vijay M Patel, MD

According to 2025 Medicare claims, Vijay Patel, MD (NPI: 1326260837) practices hematology/oncology in the Gainesville, FL market, with the plurality of this provider's patient population coming from Alachua, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32605-4308.

Patel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,214 traditional Medicare patients, billed 489,831 HCPCS/CPT codes, and received $7,311,758 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,374 prescription claims across 361 beneficiaries totaling $5,017,358 in drug costs, led by Revlimid (Lenalidomide). DME data shows 13 claims. Open Payments data shows 199 records totaling $709,926. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $88,960 to $7,311,758. Similarly, Part D prescription costs have risen steadily, from $447,515 to $5,017,358. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,984 and ending at $1,394.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	318	2,315	$88,960
2016	1,116	202,261	$1,859,139
2017	1,409	348,676	$3,419,056
2018	1,345	476,149	$4,007,844
2019	1,353	530,796	$5,053,723
2020	1,411	639,473	$6,201,786
2021	1,066	594,022	$6,652,462
2022	1,146	600,265	$6,624,284
2023	1,307	625,957	$7,422,105
2024	1,214	489,831	$7,311,758

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	204	927	$447,515
2016	222	861	$316,901
2017	210	1,192	$1,227,907
2018	204	1,220	$1,592,744
2019	229	1,210	$1,387,404
2020	243	1,371	$2,227,958
2021	257	1,463	$2,407,297
2022	280	1,537	$2,310,828
2023	338	2,062	$2,642,102
2024	361	2,374	$5,017,358

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$8,193
2016	N/R	40	$943
2017	N/R	12	$380
2018	N/R	26	$2,581
2019	N/R	N/R	N/R
2020	N/R	36	$1,738
2021	N/R	27	$4,485
2022	N/R	22	$3,809
2023	N/R	N/R	N/R
2024	N/R	13	$965

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	630	1,229	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	455	661	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	485	717	$13
36415	Insertion of needle into vein for collection of blood sample	969	2,927	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	985	3,037	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	106	2,744	$1,905,732
Xtandi	Enzalutamide	89	2,670	$1,241,174
Kisqali	Ribociclib Succinate	25	700	$366,479
Tagrisso	Osimertinib Mesylate	13	390	$216,977
Jakafi	Ruxolitinib Phosphate	11	330	$193,384

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$965

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,256	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	139	$708,670	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vijay M. Patel, MD?

Tedicare shows public-source Medicare data for Vijay M. Patel, MD (NPI 1326260837), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vijay M. Patel, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vijay M. Patel, MD?

Vijay M. Patel, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Vijay M. Patel, MD have Open Payments data?

Vijay M. Patel, MD has 199 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.